GAMMA Investing LLC increased its position in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 3,387.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 74,394 shares of the company's stock after buying an additional 72,261 shares during the period. GAMMA Investing LLC owned about 0.24% of Fulgent Genetics worth $1,257,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of FLGT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Fulgent Genetics by 13.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 50,654 shares of the company's stock valued at $936,000 after buying an additional 5,986 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Fulgent Genetics by 178.3% during the fourth quarter. Squarepoint Ops LLC now owns 41,608 shares of the company's stock worth $768,000 after acquiring an additional 26,659 shares during the last quarter. Two Sigma Advisers LP grew its stake in Fulgent Genetics by 29.7% during the fourth quarter. Two Sigma Advisers LP now owns 83,000 shares of the company's stock valued at $1,533,000 after acquiring an additional 19,000 shares in the last quarter. State of Wyoming bought a new stake in Fulgent Genetics in the 4th quarter valued at $57,000. Finally, Quantinno Capital Management LP purchased a new stake in Fulgent Genetics in the 4th quarter worth $242,000. Hedge funds and other institutional investors own 48.06% of the company's stock.
Fulgent Genetics Price Performance
Fulgent Genetics stock traded up $0.04 during midday trading on Thursday, reaching $20.30. The company's stock had a trading volume of 166,936 shares, compared to its average volume of 285,541. The stock has a market capitalization of $617.93 million, a P/E ratio of -15.26 and a beta of 1.06. The stock's 50-day simple moving average is $19.77 and its 200-day simple moving average is $18.36. Fulgent Genetics, Inc. has a 52-week low of $14.57 and a 52-week high of $25.11.
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its quarterly earnings data on Friday, May 2nd. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.22. The firm had revenue of $73.46 million for the quarter, compared to the consensus estimate of $71.26 million. Fulgent Genetics had a negative net margin of 13.94% and a negative return on equity of 2.19%. The company's revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.01) earnings per share. As a group, equities research analysts expect that Fulgent Genetics, Inc. will post -0.85 earnings per share for the current fiscal year.
Insider Buying and Selling at Fulgent Genetics
In other Fulgent Genetics news, COO Jian Xie sold 1,873 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $20.54, for a total transaction of $38,471.42. Following the sale, the chief operating officer now owns 372,631 shares in the company, valued at approximately $7,653,840.74. The trade was a 0.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 31.76% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on FLGT. Piper Sandler reissued a "neutral" rating and issued a $23.00 target price (up from $16.00) on shares of Fulgent Genetics in a report on Tuesday, May 6th. Raymond James Financial restated an "outperform" rating and issued a $25.00 price target (up previously from $24.00) on shares of Fulgent Genetics in a report on Monday, May 5th. Finally, Wall Street Zen raised Fulgent Genetics from a "sell" rating to a "hold" rating in a research report on Wednesday, March 5th.
View Our Latest Research Report on Fulgent Genetics
Fulgent Genetics Profile
(
Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Featured Stories
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
